Finivi Inc. Sells 24,340 Shares of Tempus AI, Inc. $TEM

Finivi Inc. lowered its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 69.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,684 shares of the company’s stock after selling 24,340 shares during the quarter. Finivi Inc.’s holdings in Tempus AI were worth $619,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of TEM. Royal Bank of Canada increased its position in shares of Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares during the last quarter. Rhumbline Advisers bought a new stake in Tempus AI during the first quarter valued at approximately $116,000. Prudential Financial Inc. bought a new stake in Tempus AI during the second quarter valued at approximately $276,000. Russell Investments Group Ltd. grew its stake in Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after buying an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after buying an additional 204,629 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

Shares of TEM opened at $52.05 on Monday. The firm has a market cap of $9.39 billion, a price-to-earnings ratio of -36.15 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The firm has a 50 day moving average price of $51.33 and a 200-day moving average price of $51.83.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) EPS. As a group, equities research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 4,116 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the sale, the chief accounting officer owned 74,041 shares of the company’s stock, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. This represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 723,981 shares of company stock valued at $34,879,442. 24.26% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on TEM shares. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, BTIG Research lowered their price target on Tempus AI from $80.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI has an average rating of “Hold” and an average price target of $64.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.